Brandywine Global Investment Management LLC Raises Stock Holdings in Genmab A/S Sponsored ADR $GMAB

Key Points

• Brandywine Global Investment Management LLC increased its stake in Genmab A/S by 6.0%, owning approximately $33.63 million in stock, following the acquisition of an additional 97,633 shares.
• Several large investors, including Deep Track Capital and Two Sigma Advisors, have also significantly increased their positions in Genmab A/S during the fourth quarter, indicating growing institutional interest.
• Equities analysts have a consensus rating of "Moderate Buy" for Genmab A/S, with target prices ranging between $36.00 and $46.00, underscoring positive sentiment toward the company's growth potential.

Brandywine Global Investment Management LLC boosted its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 6.0% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 1,717,397 shares of the company's stock after acquiring an additional 97,633 shares during the quarter. Brandywine Global Investment Management LLC owned 0.27% of Genmab A/S worth $33,627,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC grew its stake in Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after acquiring an additional 1,070 shares during the period. Barclays PLC grew its stake in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Genmab A/S in the 4th quarter valued at $60,000. Finally, Advisors Preferred LLC acquired a new stake in Genmab A/S in the 1st quarter valued at $84,000. Institutional investors and hedge funds own 7.07% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on GMAB shares. HC Wainwright lifted their price target on shares of Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Friday, August 15th. Truist Financial lifted their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $37.60.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB traded up $0.2950 during trading on Wednesday, hitting $24.1150. 700,310 shares of the company were exchanged, compared to its average volume of 1,434,192. The firm has a market capitalization of $15.47 billion, a PE ratio of 12.14, a P/E/G ratio of 6.80 and a beta of 0.95. Genmab A/S Sponsored ADR has a 12-month low of $17.24 and a 12-month high of $27.94. The company has a fifty day moving average price of $21.84 and a 200-day moving average price of $20.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. Research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.